KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
24 hedge funds and large institutions have $63.2M invested in KalVista Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 5 closing their positions.
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
33% more funds holding
Funds holding: 18 → 24 (+6)
21% more capital invested
Capital invested by funds: $52.2M → $63.2M (+$11M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
19.36% less ownership
Funds ownership: 79.46% → 60.09% (-19%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$8.85M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$3.26M |
| 3 |
Millennium Management
New York
|
+$2.46M |
| 4 |
NC
Nexthera Capital
New York
|
+$1.88M |
| 5 |
Renaissance Technologies
New York
|
+$923K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$18.3M |
| 2 |
VMI
VHCP Management II
New York
|
-$1.49M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$846K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$146K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$75K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BFM
26
Boothbay Fund Management
New York
| – | -$146K | -21,665 | Closed |
|
|
27
Alyeska Investment Group
Chicago,
Illinois
| – | -$75K | -11,184 | Closed |
|
|
PAM
28
Panagora Asset Management
Boston,
Massachusetts
| – | -$15K | -2,274 | Closed |
|
KALV Hedge Fund Activity: Q4 2017 in Review
24 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q4 2017, worth a combined $63.2M — up 21% from $52.2M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new KALV positions and 5 closed out — a net gain of 6 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was RA Capital Management, adding an estimated $8.85M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $18.3M sold.
- 24 institutional investors held KalVista Pharmaceuticals (KALV) as of Q4 2017, up from 18 in Q3 2017.
- Funds reported $63.2M of KalVista Pharmaceuticals stock for Q4 2017, up 21% quarter-over-quarter.
- 11 funds opened new KalVista Pharmaceuticals positions in Q4 2017 and 5 closed out, a net change of +6 holders.
- The largest KalVista Pharmaceuticals buyer in Q4 2017 was RA Capital Management, an estimated $8.85M added.
- The largest KalVista Pharmaceuticals seller in Q4 2017 was Novo Holdings A/S, an estimated $18.3M sold.
Based on aggregated 13F filings for Q4 2017.